Trending Today: 5 Names Inside

Open for Tickers Dear Reader, According to our research, there are a few trending companies that have recently received buy ratings and showing a combination of positive investor sentiment, news headlines and blog buzz. With that said, we are not recommending buying these names but we are adding them to our stock watchlist. We will continue to monitor companies to see if the momentum continues. --------------------------------------------------------------- Sponsor [FDA news shines light on this little-known clinical-stage Pharma]( Reader, This little-known clinical-stage pharma company recently received a favorable decision from the FDA and it's shining a light on its potential for significant growth. Could we be looking at 1,788% in upside potential? Free report reveals the name, ticker symbol, and 14 reasons to immediately start your research on this company. Don’t miss out on this one... [Click Here For Free Report]( --------------------------------------------------------------- [AstraZeneca, AZN]( Summary: AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. Andrew Berens analyst at SVB Securities reiterates coverage on [AstraZeneca (AZN)]( with a Buy rating and has set a price target of n/a. [TipRanks.com]( reports that [AstraZeneca]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $136.32. In addition, TradingView issued a Buy rating for [AZN]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the chart and additional details on AZN, please click here >>]( --------------------------------------------------------------- [Ameriprise Financial, AMP]( Summary: Ameriprise Financial, Inc. has been operating independently of American Express Company. Ameriprise has 4 business segments. The Advice & Wealth Management segment provides financial planning and advice, as well as full service brokerage and banking services, primarily to retail clients through the company's affiliated financial advisors. Suneet Kamath analyst at Jefferies reiterates coverage on [Ameriprise Financial (AMP)]( with a Buy rating and has set a price target of $ 355. [TipRanks.com]( reports that [Ameriprise Financial]( has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $386.78. In addition, TradingView issued a Sell rating for [AMP]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. [For the chart and additional details on AMP, please click here >>]( --------------------------------------------------------------- Sponsor [Forget Tesla... Apple Car May Be The #1 EV Play]( [Click here to learn more.]( --------------------------------------------------------------- [KBR, KBR]( Summary: KBR, Inc. delivers science, technology and engineering solutions to governments and companies around the world. The company's capabilities and offerings include Scientific research like quantum science and computing, health and human performance, materials science, life science research, and earth sciences. Mariana Perez analyst at Bank of America Securities reiterates coverage on [KBR (KBR)]( with a Buy rating and has set a price target of $ 70. [TipRanks.com]( reports that [KBR]( has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $68.00. In addition, TradingView issued a Neutral rating for [KBR]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the chart and additional details on KBR, please click here >>]( --------------------------------------------------------------- [Celsius Holdings, CELH]( Summary: Celsius Holdings, Inc. specializes in commercializing healthier, nutritional functional foods, beverages and dietary supplements. Celsius Holdings, Inc. markets Celsius', the calorie burner, through its wholly-owned operating subsidiary, Celsius, Inc. The Company sells its products through grocery, drug, convenience, club and mass, and health and fitness channels. Gerald Pascarelli analyst at Wedbush reiterates coverage on [Celsius Holdings (CELH)]( with a Buy rating and has set a price target of $ 115. [TipRanks.com]( reports that [Celsius Holdings]( has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $117.57. In addition, TradingView issued a Neutral rating for [CELH]( over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. [For the chart and additional details on CELH, please click here >>]( --------------------------------------------------------------- Sponsor [Why This Boston Building Should Scare the Hell out of You]( Americans have no idea that at this very moment — their very lives are being threatened by the “experts” at work in this office tower. Because this building is the command center for one of the most devastating plots in American history ... one that’s going to change life here in America forever. [Ian King’s finally going public with what he’s discovered.]( --------------------------------------------------------------- [Grupo Aeroportuario Del Centro, OMAB]( Summary: OMA operates and manages 13 international airports in the north and central regions of Mexico. OMA's airports serve Monterrey, M'xico's third largest metropolitan area, the tourist destinations of Acapulco, Mazatlan, and Zihuatanejo, and nine other regional centers and border cities. [Bruno Amorim analyst at Goldman Sachs reiterates coverage on]( Aeroportuario Del Centro (OMAB)]( with a Buy rating and has set a price target of $ 76. [TipRanks.com]( reports that [Grupo Aeroportuario Del Centro]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $76.00. In addition, TradingView issued a Buy rating for [OMAB]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [For the chart and additional details on OMAB, please click here >>]( --------------------------------------------------------------- Sponsor [Millionaire Trader Reveals:]( How to Make One Type of Trade – Every Month – and Start Making All the Money You Need to Fund Your Retirement. [Click here for the name of the currency trade.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [wallstreetanalystpress.com]( --------------------------------------------------------------- Sponsor [Will FDA News Lift This Stock?]( [Click Here Now.]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( WallStreetAnalystPress.com Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to WallStreetAnalystPress. WallStreetAnalystPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123 [UNSUBSCRIBE](